Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL2-C52H6 | Canine | Canine IL-13 R alpha 2 Protein, His Tag (MALS verified) |
|
|
|
IL2-H82E6 | Human | Biotinylated Human IL-13 R alpha 2 Protein, His,Avitag™ (MALS verified) |
|
|
|
IL2-R52H5 | Rhesus macaque | Rhesus macaque IL-13 R alpha 2 Protein, His Tag |
|
|
|
IL2-H5256 | Human | Human IL-13 R alpha 2 Protein, Fc Tag (MALS verified) |
|
|
|
IL2-HF2H3 | Human | FITC-Labeled Human IL-13 R alpha 2 Protein, His Tag |
|
|
|
IL2-H52H5 | Human | Human IL-13 R alpha 2 Protein, His Tag (MALS verified) |
|
|
Loaded Human IL-13, Fc Tag (Cat. No. IL3-H5256) on Protein A Biosensor, can bind Human IL-13 R alpha 2, His Tag (Cat. No. IL2-H52H5) with an affinity constant of 6.09 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Immobilized Biotinylated Human IL-13 R alpha 2, His,Avitag (Cat. No. IL2-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 with a linear range of 0.4-2 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
MB-101 (Mustang Bio) | MB-101 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms | Details |
IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Medulloblastoma; Ependymoma; Squamous Cell Carcinoma of Head and Neck; Adenoma, Islet Cell; Adenocarcinoma of Lung; Glioblastoma; Adrenocortical Carcinoma; Neuroendocrine Tumors; Uveal melanoma; Breast Neoplasms; Thyroid Neoplasms; Paraganglioma; Melanoma | Details | |
IL13Rα2 targeted CAR-T cell(Yooyoung) | YYB-103; CLM-103 | Phase 1 Clinical | Yooyoung | Glioma; Amyotrophic Lateral Sclerosis | Details |
IL13Rα2 CAR-T cell therapy(TCRCure Biopharma) | Phase 1 Clinical | Tcrcure Biopharma Ltd | Glioma | Details | |
MT-026 | MT-026 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
MB-101 (Mustang Bio) | MB-101 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms | Details |
IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Medulloblastoma; Ependymoma; Squamous Cell Carcinoma of Head and Neck; Adenoma, Islet Cell; Adenocarcinoma of Lung; Glioblastoma; Adrenocortical Carcinoma; Neuroendocrine Tumors; Uveal melanoma; Breast Neoplasms; Thyroid Neoplasms; Paraganglioma; Melanoma | Details | |
IL13Rα2 targeted CAR-T cell(Yooyoung) | YYB-103; CLM-103 | Phase 1 Clinical | Yooyoung | Glioma; Amyotrophic Lateral Sclerosis | Details |
IL13Rα2 CAR-T cell therapy(TCRCure Biopharma) | Phase 1 Clinical | Tcrcure Biopharma Ltd | Glioma | Details | |
MT-026 | MT-026 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
This web search service is supported by Google Inc.